NEW YORK (GenomeWeb) – Profiling mutations in a few hundred genes appears to be a promising method for identifying mutation-rich tumors that may respond to drugs that target the immune checkpoint pathway, according to a new research study led by Foundation Medicine.
Get the full story This story is free
for registered users
Registering provides access to this and other free content.
Already have an account?
.
Be the first to comment